CN1171952A - Traditional Chinese medicine preparation for eradicating Helicobacter phlori - Google Patents
Traditional Chinese medicine preparation for eradicating Helicobacter phlori Download PDFInfo
- Publication number
- CN1171952A CN1171952A CN 97105771 CN97105771A CN1171952A CN 1171952 A CN1171952 A CN 1171952A CN 97105771 CN97105771 CN 97105771 CN 97105771 A CN97105771 A CN 97105771A CN 1171952 A CN1171952 A CN 1171952A
- Authority
- CN
- China
- Prior art keywords
- root
- medicine preparation
- chinese medicine
- grams
- portions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a Chinese herbal medicine preparation for resisting pyloric helicobacterium to cure gastritis. Its composition includes the Chinese herbal medicines of coptis root, scutellaria root, phellodendron bark, poria, mume fruit, crataegus fruit, sanguisorba root, saussurea root, evodia fruit; may also include one to five kinds of astragalus root, unripe bitter orange, bletilla tuber, codonopsis root and ovate atractylodes root (dosage of each of them is 100-5000 weight portions), further includes furazolidone (10-200 portions), colloid bismuth agent (10-300 portions) and metronidazole (10-300 portions). Its dosage form can be mixture, capsule, powder or tablet. Said invented preparation possesses the functions of clearing heat and transforming dampness, nourishing stomach and fortifying spleen, rectifying qi and harmonizing the center, relieving inflammation and alleviating pain, so that it can be used for curing chronic gastritis and peptic ulcer, etc..
Description
The present invention relates to the Chinese herbal and crude drugs preparations of anti-helicobacter pylori treatment gastritis, belong to medical technical field.
Nineteen eighty-three Australia scholar's Warren (Waren) and Marshall (Marshall) are isolated helicobacter pylori (Helicobacter Pylori) from gastric mucosa, abbreviation HP.After studies have shown that in a large number: HP and chronic gastritis, peptic ulcer, even the morbidity of gastric cancer, development, recur and a series of complication of causing (as hemorrhage etc.) all have substantial connection.HP can settle down at normal person's gastric mucosa and cause acute or chronic gastritis, and HP still is the important pathogenic bacteria of peptic ulcer.Zhang Wandai etc. are in " China digestion magazine " 1995, and 15:277 delivers " seroepidemiological survey of gastric cancer nature crowd helicobacter pylori infections " article and points out, the total infection rate of population of China is average 50.5, is the higher country of HP infection rate.How to effect a radical cure HP, control and the above-mentioned disease of blocking-up generation, recur and cancerate, extremely important medical value is arranged.At present, the standard scheme of internationally recognized radical cure HP is a triple therapy, comprises colloidal bismuth, metronidazole, amoxicillin or tetracycline, day obeys four times, and two all radical rates reach 30% but the disadvantage of this therapy is side effect about 90%, and dosage is big, and expenses for medicine is very high.Recently, the anti-HP research of Chinese medicine comes into one's own, and the danger North Sea etc. are at " Chinese medicine journal " 1993,8 (5): 25-26 delivers " Chinese medicine is to the experimentation of helicobacter pylori inhibitory or killing effect ", article points out have HP the infected's differential diagnosis in tcm how relevant with heat, and treatment by Chinese herbs is wet based on the heat clearing away bath.
The objective of the invention is to remedy the deficiency of prior art, a kind of good effect, anti-HP herb mixture that cost is low are provided.
The objective of the invention is to be achieved through the following technical solutions.
The Chinese herbal medicine that Chinese medicine preparation of the present invention comprises has Rhizoma Coptidis, Radix Scutellariae, Cortex Phellodendri, Poria, Fructus Mume, Fructus Crataegi, Radix Sanguisorbae, the Radix Aucklandiae, Fructus Evodiae.
Chinese medicine preparation of the present invention also can add 1 to 5 kind of following Chinese herbal medicine:
The Radix Astragali, Fructus Aurantii Immaturus, the Pseudobulbus Bletillae (Rhizoma Bletillae), Radix Codonopsis, the Rhizoma Atractylodis Macrocephalae.
The consumption of Chinese herbal medicine of below respectively distinguishing the flavor of is 100-5000 part, weight portion, down with.
Chinese medicine preparation of the present invention can be made decoction liquor according to a conventional method, directly takes for the people; Also decoction liquor can be condensed into mixture, or electuary is made in the concentrated solution sugaring, perhaps with concentrated solution dry levigate after, make capsule or tablet.The same prior art of preparation method.
Chinese medicine preparation of the present invention also can comprise furazolidone 10-200 part, colloidal bismuth 10-300 part, metronidazole 10-300 part.
Subjects of the present invention and method:
Select the out-patient in 12-68 year, detect through gastroscopy and gastric mucosa HP in three days, confirm to have the chronic gastritis patient of HP infection, do not accept bismuth or antibiotic therapy in 4 weeks, do not take nonsteroidal medicine or 17-hydroxy-11-dehydrocorticosterone, no severe cardiac, lung, hepatic and renal function injure because of other diseases.
Patient is divided into some groups at random, and administration respectively early services once with sleep evening before the meal by doses preceding half an hour, serve on 14 days.Change of illness state and relevant untoward reaction are write down in record patient Qinghua road symptom and further consultation at 2,4,6 weekends after taking medicine before testing, and reach before treating and do gastroscope, histopathologic examination and HP detection the course of treatment after the end 4 weeks; Reach before the treatment and finish to do the conventional regulating liver-QI of hematuria, kidney function test the course of treatment.
HP detects:
Adopting the dyeing of tissue slice silver, rapid urease test, Ge Lamu (Gram) Albert'stain Albert, poly-ribozyme chain reaction to carry out HP before and after the treatment detects.Two kinds of method positive persons are decided to be the HP positive in the said method, and two kinds of method negative patients are decided to be the HP feminine gender, and only a kind of method positive person does not classify selected object as.The HP eradication rate: treatment stopped for 4 weeks, and tissue slice HP inspection, rapid urease test, the equal negative patient of Ge Lamu (Gram) Albert'stain Albert inspection bacterium are decided to be HP and eradicate.
Efficacy evaluation:
Remission, digestive system clinical symptoms degree with do not have, light, in, weigh 4 grades of evaluations, reduce one-level person after all treatments and belong to improvement, reduce secondary or the above person of secondary and belong to produce effects; The activeness inflammation with 0, I, II, the evaluation of III4 level, all treatments back reduces one-level person and belongs to improvement, is reduced to 0 grade and belongs to the disappearance of activeness inflammation.
Statistical procedures: ranked data detect with Ridit, and enumeration data detects with card side, and measurement data detects with t.
Clinical efficacy:
(1) clinical symptom remission: treatment back patient's symptom all has clear improvement, wherein to alleviate upper abdominal pain, acid regurgitation, feel sick, abdominal distention is evident in efficacy.Concrete data see Table 2.
(2) histopathology is improved: the patient all improves through treatment chronic inflammatory disease and activeness inflammation.Result of the test sees Table 4.
The HP eradication rate is at 84%-100%, and is as shown in table 5.Have no adverse reaction.
The invention will be further described below in conjunction with embodiment.Embodiment 1. capsule preparations
Rhizoma Coptidis 1500 grams, Radix Scutellariae 1500 grams, Cortex Phellodendri 1000 grams, Poria 1000 grams, Fructus Mume 1000 grams, Fructus Crataegi 1000 grams, Radix Sanguisorbae 1000 grams, the Radix Aucklandiae 1500 grams, Fructus Evodiae 1000 grams.
Said herbal medicine is added 10 times in water (weight, down with) decocted two hours, filter, add water again and decocted two hours for 8 times, filter, merges twice filtrate, be concentrated into the thick paste shape, drying, levigate, 120 mesh sieves, 1000 capsules of packing into are made capsule formulation.
Function with cure mainly: clearing away heat and eliminating dampness, nourishing stomach and spleen, regulate the flow of vital energy and in.Be used for chronic gastritis, peptic ulcer, especially the accompanied with Helicobacter pylori infection person.
Usage and consumption: half an hour ante cibum is oral, a 2-6 grain, and every day 2-4 time, 14-28 days is a course of treatment.Embodiment 2. electuaries
Rhizoma Coptidis 1500 grams, Radix Scutellariae 1500 grams, Cortex Phellodendri 1000 grams, Poria 1000 grams, Fructus Mume 1000 grams, Fructus Crataegi 1000 grams, Radix Sanguisorbae 1000 grams, the Radix Aucklandiae 1500 grams, Fructus Evodiae 1000 grams, the Radix Astragali 1000 grams, Fructus Aurantii Immaturus 1000 grams, the Pseudobulbus Bletillae (Rhizoma Bletillae) 1000 grams, Radix Codonopsis 1000 grams, the Rhizoma Atractylodis Macrocephalae 1000 grams.
Medical herbs decocts with water, and method is with embodiment 1, and different is, fried liquid was left standstill 24 hours, gets supernatant, and evaporation and concentration is to proportion 1.14 (95 ℃ time measure), thick extractum.Cane sugar powder is stirred an amount of the adding in the thick extractum, make soft material, granulate with 10 mesh sieves, dry below 80 ℃, heavily cross once sieve, the Oleum menthae of ethanol dilution is sprayed into, put in the airtight container and placed 24 hours.By dose in the side is 1000 clothes, and each dose (gram)=finished product gross weight (gram)/1000 calculates the back by each dose dress plastic bag, and is airtight.
Function with cure mainly: clearing away heat and eliminating dampness, nourishing stomach and spleen, regulate the flow of vital energy and in.Be used for chronic gastritis, peptic ulcer, the person that especially merges the helicobacter pylori infections.
Usage and consumption: ante cibum, half an hour, warm water was taken after mixing it with water, every day 2-4 time, and each 1-2 bag, 14-28 days is a course of treatment.Embodiment 3. compound tablet
Rhizoma Coptidis 3000 grams, Radix Scutellariae 3000 grams, Cortex Phellodendri 2000 grams, Poria 2000 grams, Fructus Mume 2000 grams, Fructus Crataegi 2000 grams, Radix Sanguisorbae 2000 grams, the Radix Astragali 3000 grams, Fructus Aurantii Immaturus 2000 grams, furazolidone 75 gram colloid citron bismuths 200 grams, metronidazole 150 grams.
The method of preceding 9 flavor medical herbs by embodiment 1 decocted with water, filters, concentrates, add the ethanol of 2.5 times of concentrated solution weight, leave standstill, make precipitation, the leaching supernatant is concentrated into proportion 1.4.Again that back three kinds of drug mills are thin, mix, add in the concentrated solution.Add necessary adjuvant by the pharmacy industry known technology in addition, mixing is made granule, and drying is put coldly, and spray is with Oleum menthae, and mixing after airtight placement a few hours, is pressed into 2000, and sugar coating promptly.
Function with cure mainly: clearing away heat and eliminating dampness, nourishing stomach and spleen, regulate the flow of vital energy and in, anti-inflammatory analgetic.Be used for chronic gastritis, peptic ulcer, the person that especially merges the helicobacter pylori infections.
Usage and consumption: ante cibum, half an hour, warm water was taken after mixing it with water, and every day 2-4 time, each 4,14-28 days is a course of treatment.
Clinical symptoms performance before table 1. treatment
Upper abdominal pain acid regurgitation abdomen dim gas anorexia embodiment 1 example several 35 21 15 36 33 16 (total 46 examples) % 72.9 43.8 31.3 75 68.9 33.3 embodiment 3 example several 32 19 14 35 31 14 (total 48 examples) %, the 69.6 41.3 30.4 76.1 67.4 30.4 tables 2. treatment back clinical symptom remission situations (state of an illness distributes as shown in table 1) that rise of feeling sick
Execute the effective no change total effective rate of produce effects
The routine number of the routine number of routine number (%) (%) (%) is upper abdominal pain 1 15 (46.9) 15 (46.9) 2 (6.3) 93.8 (%)
3 16 (45.7) 17 (48.6) 2 (5.7) 94.3 acid regurgitations 18 (42.1) 9 (47.4) 1 (5.3) 89.5
39 (42.9) 10 (47.6) 2 (9.5) 90.5 feel sick 4 (28.6) 9 (64.3) 1 (7.1) 92.9
36 (40) 8 (53.3) 1 (6.6) 93.3 abdomens rise 1 17 (48.6) 20 (55.5) 1 (2.9) 84.8
3 14 (38.8) 16 (45.7) 2 (5.5) 94.3 dim gas 1 12 (38.7) 14 (45.2) 2 (6.5) 83.9
3 13 (39.4) 15 (45.5) 3 (9.1) 84.8 anorexia 15 (35.7) 6 (42.9) 2 (14.3) 78.6
3 6(37.5) 6(37.5) 2(12.5) 75
Chronic gastritis pathology histology performance before table 3. treatment
Chronic inflammatory disease example number activeness inflammation
In light heavily atrophy intestinal heteroplasia light in heavy embodiment 1 example several 9 19 18 11 90 34 16 13 5 (total 46 examples) % 18.8 41.3 37 23.9 19.6 73.9 embodiment 3 example several 9 22 28 13 83 36 11 19 6 (total 48 examples) % 18.8 45.8 58.3 27.1 16.6 6.3 78.3
Table 4. treatment back chronic gastritis pathology histology shows situation
(state of an illness distributes as shown in table 3)
Chronic inflammatory disease activeness inflammation
The effective no change of produce effects disappears and takes a turn for the better
The example routine number of the routine number of the routine number of the routine number of number (%) (%) (%) (%) (%) embodiment 1 11 (23.9) 30 (65.2) 3 (6.5) 15 (44.1) 17 (50) embodiment 39 (18.8) 36 (75) 2 (4.2) 28 (77.8) 8 (22.2)
Table 5.HP eradicates situation
Total routine number treatment back HP (-) eradication rate (%) embodiment 1 46 40 87.4 embodiment 2 42 35 85.7 embodiment 3 48 48 100
Claims (5)
1. an anti-helicobacter pylori Chinese medicine preparation is characterized in that, comprises that Chinese herbal medicine has Rhizoma Coptidis, Radix Scutellariae, Cortex Phellodendri, Poria, Fructus Mume, Fructus Crataegi, Radix Sanguisorbae, the Radix Aucklandiae, Fructus Evodiae.
2. anti-helicobacter pylori Chinese medicine preparation as claimed in claim 1 is characterized in that, also has 1 to 5 kind of following Chinese herbal medicine: the Radix Astragali, Fructus Aurantii Immaturus, the Pseudobulbus Bletillae (Rhizoma Bletillae), Radix Codonopsis, the Rhizoma Atractylodis Macrocephalae.
3. anti-helicobacter pylori Chinese medicine preparation as claimed in claim 1 is characterized in that the consumption of Chinese herbal medicine is the 100-5000 weight portion.
4. anti-helicobacter pylori Chinese medicine preparation as claimed in claim 1 is characterized in that, also has furazolidone 10-200 part, colloidal bismuth 10-300 part, metronidazole 10-300 part.
5. anti-helicobacter pylori Chinese medicine preparation as claimed in claim 1 is characterized in that, pharmaceutical formulation is one of following:
A. mixture, b. capsule, c. electuary, d. tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97105771A CN1069041C (en) | 1997-04-11 | 1997-04-11 | Traditional Chinese medicine preparation for eradicating Helicobacter phlori |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97105771A CN1069041C (en) | 1997-04-11 | 1997-04-11 | Traditional Chinese medicine preparation for eradicating Helicobacter phlori |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1171952A true CN1171952A (en) | 1998-02-04 |
| CN1069041C CN1069041C (en) | 2001-08-01 |
Family
ID=5168075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN97105771A Expired - Fee Related CN1069041C (en) | 1997-04-11 | 1997-04-11 | Traditional Chinese medicine preparation for eradicating Helicobacter phlori |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1069041C (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1090951C (en) * | 1998-03-05 | 2002-09-18 | 孙小祥 | Traditional Chinese medicine for curing gastrointestinal disease |
| CN1321672C (en) * | 2004-10-14 | 2007-06-20 | 上海市普陀区中心医院 | Chinese traditional medicine compound preparation for treating chronic gastritis accompanied with Helicobacter pylori infection |
| CN100406064C (en) * | 2006-04-26 | 2008-07-30 | 中国人民解放军第三军医大学 | Formulation for treating disease infected by helicobacter pylori |
| CN104491103A (en) * | 2014-12-01 | 2015-04-08 | 郭文喜 | Traditional Chinese medicine composition for treating ulcerative colitis |
| CN104887780A (en) * | 2015-05-27 | 2015-09-09 | 南昌大学 | Preparation method of active dark plum extract and application in inhibition of helicobacter pylori |
| CN105998686A (en) * | 2016-06-15 | 2016-10-12 | 黄晓泉 | Stomach medicine preparation, preparation method and application thereof |
| WO2017020279A1 (en) * | 2015-08-05 | 2017-02-09 | 浙江众康药业有限公司 | Uses of composition comprising polygonum capitatum and coptis roots in preparation of drugs for resisting against helicobacter pylori |
| WO2017020280A1 (en) * | 2015-08-05 | 2017-02-09 | 浙江众康药业有限公司 | Uses of composition comprising polygonum capitatum and coptis roots in preparation of drugs for treating gastritis |
| WO2017020862A1 (en) * | 2015-08-05 | 2017-02-09 | 浙江众康药业有限公司 | Application of polygonum capitatum composition in treating gastritis |
| CN107898887A (en) * | 2018-01-11 | 2018-04-13 | 孟凌冰 | A kind of Chinese medicine for treating helicobacter pylori |
| CN111358721A (en) * | 2020-04-12 | 2020-07-03 | 广东医创时代科技发展有限公司 | Chinese herbal medicine oral care product for preventing and treating helicobacter pylori infection of oral cavity and various oral diseases |
-
1997
- 1997-04-11 CN CN97105771A patent/CN1069041C/en not_active Expired - Fee Related
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1090951C (en) * | 1998-03-05 | 2002-09-18 | 孙小祥 | Traditional Chinese medicine for curing gastrointestinal disease |
| CN1321672C (en) * | 2004-10-14 | 2007-06-20 | 上海市普陀区中心医院 | Chinese traditional medicine compound preparation for treating chronic gastritis accompanied with Helicobacter pylori infection |
| CN100406064C (en) * | 2006-04-26 | 2008-07-30 | 中国人民解放军第三军医大学 | Formulation for treating disease infected by helicobacter pylori |
| CN104491103A (en) * | 2014-12-01 | 2015-04-08 | 郭文喜 | Traditional Chinese medicine composition for treating ulcerative colitis |
| CN104887780A (en) * | 2015-05-27 | 2015-09-09 | 南昌大学 | Preparation method of active dark plum extract and application in inhibition of helicobacter pylori |
| WO2017020279A1 (en) * | 2015-08-05 | 2017-02-09 | 浙江众康药业有限公司 | Uses of composition comprising polygonum capitatum and coptis roots in preparation of drugs for resisting against helicobacter pylori |
| WO2017020280A1 (en) * | 2015-08-05 | 2017-02-09 | 浙江众康药业有限公司 | Uses of composition comprising polygonum capitatum and coptis roots in preparation of drugs for treating gastritis |
| WO2017020862A1 (en) * | 2015-08-05 | 2017-02-09 | 浙江众康药业有限公司 | Application of polygonum capitatum composition in treating gastritis |
| CN105998686A (en) * | 2016-06-15 | 2016-10-12 | 黄晓泉 | Stomach medicine preparation, preparation method and application thereof |
| CN107898887A (en) * | 2018-01-11 | 2018-04-13 | 孟凌冰 | A kind of Chinese medicine for treating helicobacter pylori |
| CN107898887B (en) * | 2018-01-11 | 2020-11-24 | 孟凌冰 | Traditional Chinese medicine for treating helicobacter pylori |
| CN111358721A (en) * | 2020-04-12 | 2020-07-03 | 广东医创时代科技发展有限公司 | Chinese herbal medicine oral care product for preventing and treating helicobacter pylori infection of oral cavity and various oral diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1069041C (en) | 2001-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1203807A (en) | Medicine for curing recurrent stomatocace and Behcet's syndrome | |
| CN103751739A (en) | Traditional Chinese medicine composition for treating chronic gastritis, application of composition in preparation of medicine for treating chronic gastritis, and preparation method of composition | |
| CN1069041C (en) | Traditional Chinese medicine preparation for eradicating Helicobacter phlori | |
| CN101757281B (en) | Traditional Chinese medicine composition for treating gastrointestinal disease and preparation method thereof | |
| CN103182059B (en) | Traditional Chinese medicine composition for treating chronic gastritis, and application thereof | |
| CN107362292A (en) | It is a kind of that there is the composition for improving female genitourinary system inflammation, preparation method and application | |
| CN113713031B (en) | Traditional Chinese medicine composition for treating helicobacter pylori infection, preparation method and application | |
| CN113750141A (en) | Composition for treating hashimoto thyroiditis and preparation method and application thereof | |
| CN103479824B (en) | A kind ofly treat Chinese medicine composition of chronic periodontitis and gastritis and preparation method thereof | |
| CN1056752C (en) | Traditional Chinese medicine oral administration liquid for anti-cancer and its preparing method | |
| CN1903347A (en) | Medicine composition for treating alimentary canal diseases, prepn. method and application thereof | |
| CN112773878A (en) | Traditional Chinese medicine composition for treating metabolic-related fatty liver disease and preparation method thereof | |
| CN1130515A (en) | Chinese drug for treating chronic colitis | |
| CN111329959A (en) | Compound traditional Chinese medicine for intervening gastric cancer infiltration and metastasis and preparation method thereof | |
| CN1879771A (en) | Medicine for treating stomachache and method for preparing same | |
| CN102430008A (en) | Chinese medicinal composition for treating gastrointestinal disease and preparation method thereof | |
| CN1059117C (en) | Katsutoxin pill for tumor and preparing method thereof | |
| CN106563076B (en) | Medicine for treating stomach disease and its preparing method | |
| CN101683421B (en) | Applications of traditional Chinese medicine composition in preparation of medicament for treating repetitive respiratory tract infection | |
| CN104984237A (en) | Traditional Chinese medicine composition and preparation method | |
| CN1060390C (en) | Chinese medicine for gastropathy related to pyloric spiri-bacillus | |
| CN112206298A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating diarrhea | |
| CN114796432B (en) | Traditional Chinese medicine composition for treating gastritis and preparation method thereof | |
| CN114832078B (en) | Traditional Chinese medicine composition for spleen deficiency and dampness retention type PPI (PPI-dependent gastroesophageal reflux disease) | |
| CN101167915B (en) | Traditional Chinese medicine for treating chronic superficial gastritis and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |